Extrasynaptic GABAA receptors in the crosshairs of hormones and ethanol.
Gamma-aminobutyric acid (GABA) is the main chemical inhibitory neurotransmitter in the brain. In the central nervous system (CNS) it acts on two distinct types of receptor: an ion channel, i.e., an "ionotropic" receptor permeable to Cl- and HCO3- (GABAA receptors) and a G-protein coupled "metabotropic" receptor that is linked to various effector mechanisms (GABAB receptors). This review will summarize novel developments in the physiology and pharmacology of GABAA receptors (GABAARs), specifically those found outside synapses. The focus will be on a particular combination of GABAAR subunits sensitive to ovarian and adrenal cortical steroid hormone metabolites that are synthesized in the brain (neurosteroids) and to sobriety impairing concentrations of ethanol. These receptors may be the final common pathway for interactions between ethanol and ovarian and stress-related neurosteroids.
Mody
Istvan
I
Department of Neurology NRB1 575D, The David Geffen School of Medicine at UCLA, 635 Charles Young Dr S., Los Angeles, CA 90095, United States. mody@ucla.edu
D000818:Animals; D000431:Ethanol / Q000494:pharmacology*; D006728:Hormones / Q000502:physiology*; D006801:Humans; D011963:Receptors, GABA-A / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism*
D006728:Hormones; D011963:Receptors, GABA-A; D000431:Ethanol
Science. 1986 May 23;232(4753):1004-7
2422758
J Neurosci. 2003 Nov 26;23(34):10934-43
14645489
Neuron. 1989 Sep;3(3):327-37
2561970
Am J Psychiatry. 1994 Oct;151(10):1503-4
8092343
Mol Pharmacol. 1996 Mar;49(3):567-79
8643098
J Neurosci. 1996 Nov 1;16(21):6648-56
8824305
J Neurosci. 1998 Mar 1;18(5):1693-703
9464994
Mol Neurobiol. 1998 Aug;18(1):35-86
9824848
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44
14623958
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15218-23
14625373
Ann N Y Acad Sci. 2003 Dec;1007:42-53
14993039
J Neural Transm (Vienna). 2004 Jul;111(7):931-9
15206007
CNS Drugs. 2004;18(7):453-68
15139800
Trends Neurosci. 2004 May;27(5):262-9
15111008
Trends Neurosci. 2004 Sep;27(9):569-75
15331240
J Neurosci. 2004 Sep 22;24(38):8379-82
15385620
Prog Biophys Mol Biol. 2005 Jan;87(1):3-16
15471587
Life Sci. 2004 Nov 19;76(1):1-8
15501475
Ann N Y Acad Sci. 1999 Apr 30;868:645-53
10414349
Neuroscience. 2005;131(2):397-405
15708482
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
Nat Neurosci. 2005 Mar;8(3):339-45
15696164
Neurosci Behav Physiol. 2005 Mar;35(3):253-66
15875487
Nat Neurosci. 2005 Jun;8(6):797-804
15895085
Nat Rev Neurosci. 2005 Jul;6(7):565-75
15959466
Obstet Gynecol. 2005 Nov;106(5 Pt 1):1071-83
16260528
Neuroscience. 2005;136(2):457-66
16226387
J Neurophysiol. 2005 Dec;94(6):4491-501
16162835
Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):3-8
16377359
Curr Opin Pharmacol. 2006 Feb;6(1):30-6
16368265
Nature. 2006 Mar 23;440(7083):448-55
16554804
J Neurophysiol. 2006 May;95(5):2796-807
16452257
Psychopharmacology (Berl). 2006 Jun;186(3):323-33
16193334
Curr Top Med Chem. 2006;6(10):935-40
16787267
Curr Top Med Chem. 2006;6(10):941-8
16787268
Cereb Cortex. 2006 Aug;16(8):1134-41
16221925
Exp Physiol. 2006 Jul;91(4):655-60
16740643
J Womens Health Gend Based Med. 1999 Oct;8(8):1043-52
10565662
Neuroscience. 2000;101(4):815-50
11113332
Nat Rev Neurosci. 2001 Apr;2(4):240-50
11283747
Cell Mol Life Sci. 2001 Aug;58(9):1263-75
11577983
J Neurosci. 2002 Mar 1;22(5):1541-9
11880484
Br J Pharmacol. 2002 Aug;136(7):965-74
12145096
Nat Neurosci. 2002 Aug;5(8):721-2
12118257
Med Care. 2002 Nov;40(11):1101-12
12409855
Trends Pharmacol Sci. 2003 Mar;24(3):103-6
12628349
Arch Womens Ment Health. 2003 Feb;6(1):23-41
12715262
Psychoneuroendocrinology. 2003 Aug;28 Suppl 3:1-23
12892987
J Neurosci. 2003 Nov 19;23(33):10650-61
14627650
Alcohol Clin Exp Res. 1990 Apr;14(2):152-7
2190478